Top VA pharmaceutical preparation manufacturing contractors
In the 12 months ending Oct 5, 2026, the Department of Veterans Affairs obligated $11.1B in net prime contract dollars under NAICS 325412, down 5.8% from $11.8B in the preceding 12 months. 146 prime contractors received positive obligations, and 1 of them accounted for 80% of that spend.
Prime contracts funded by the Department of Veterans Affairs. Latest 12 months: Oct 6, 2025 to Oct 5, 2026. Source: USAspending.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year (October to September).
Top VA contractors for NAICS 325412
Ranked by positive obligations in the latest 12 months. Share is of all positive obligations in this market.
| # | Contractor | Latest 12 mo | Prior 12 mo | Share | Rank change |
|---|---|---|---|---|---|
| 1 | Mckesson Corporation | $10.8B | $11.6B | 97.2% | — |
| 2 | Exelan Pharmaceuticals Inc | $100.1M | $1.5M | 0.9% | ▲ 22 |
| 3 | Novartis Pharmaceuticals Corporation | $39.3M | $15.2M | 0.4% | ▲ 1 |
| 4 | Progenics Pharmaceuticals Inc | $38.6M | $36.4M | 0.4% | ▼ 2 |
| 5 | Cardinal Health 414, LLC | $22.1M | $25.0M | 0.2% | ▼ 2 |
| 6 | RLS (USA) Inc. | $11.1M | $4.7M | 0.1% | ▲ 4 |
| 7 | Bristol-Myers Squibb Company | $9.8M | $7.6M | 0.1% | — |
| 8 | Petnet Solutions, Inc. | $8.8M | $3.0M | 0.1% | ▲ 9 |
| 9 | Sofie Co. | $5.9M | $12.0M | 0.1% | ▼ 4 |
| 10 | Optum Infusion Services 308, LLC | $5.2M | $1.1M | 0.1% | ▲ 25 |
| 11 | Nuclear Diagnostic Products, Inc | $4.2M | $1.2M | 0.0% | ▲ 19 |
| 12 | Medi-Physics, Inc. | $3.9M | $3.3M | 0.0% | ▲ 3 |
| 13 | Jubilant Draximage Radiopharmacies, Inc. | $3.6M | $6.4M | 0.0% | ▼ 5 |
| 14 | Bracco Diagnostics Inc. | $3.2M | $3.6M | 0.0% | — |
| 15 | Pharmacy Buying Association, Inc. | $3.0M | $4.5M | 0.0% | ▼ 3 |
What changed in the last 12 months
Contractors with the largest change in reported obligations versus the preceding 12 months.
Largest gains
- Exelan Pharmaceuticals Inc$1.5M → $100.1M (+$98.6M) · now #2
- Novartis Pharmaceuticals Corporation$15.2M → $39.3M (+$24.1M) · now #3
- RLS (USA) Inc.$4.7M → $11.1M (+$6.4M) · now #6
Largest declines
- Mckesson Corporation$11.6B → $10.8B (−$769.3M) · now #1
- Advanced Accelerator Applications USA Inc−$885K → −$9.1M (−$8.2M) · no latest-period obligations
- Golden State Medical Supply, Inc.$7.8M → −$301 (−$7.8M) · no latest-period obligations
New to this market
19 contractors received their first obligations in this market (since FY2022) during the latest 12 months. The largest:
| Contractor | First obligation | Latest 12 mo |
|---|---|---|
| Guardian Pharmacy of Tennessee One, LLC | Sep 23, 2026 | $2.3M |
| ELI Lilly and Company | Oct 6, 2025 | $286K |
| Sagent Pharmaceuticals, Inc | Aug 11, 2026 | $276K |
| Partner Therapeutics, Inc. | Apr 10, 2026 | $235K |
| Covermymeds Pharmacy LLC | Jan 16, 2026 | $208K |
| Sina Drug LLC | Jul 9, 2026 | $188K |
| Neurotech Pharmaceuticals, Inc | Feb 27, 2026 | $188K |
| Asem Solutions LLC | Feb 17, 2026 | $166K |
Where the money comes from
Funding sub-agencies within the Department of Veterans Affairs, latest 12 months. The funding organization can differ from the office that runs the requirement.
| Funding sub-agency | Latest 12 mo | Prior 12 mo | Change |
|---|---|---|---|
| Department of Veterans Affairs | $11.1B | $11.8B | Down $686.4M (5.8%) |
Potential recompetes
Large awards in this market whose current period of performance ends in the next 18 months. Treat these as research leads: options, extensions, and follow-on vehicles often change the timing.
| Award | Incumbent | Obligated | Current end |
|---|---|---|---|
| 36C26226N0112 | Novartis Pharmaceuticals Corporation PLUVICTO AND LUTATHERA | $4.3M | Oct 31, 2026 |
| 36C24726F0053 | Exelan Pharmaceuticals Inc LENALIDOMIDE CAPSULES | $4.8M | Dec 7, 2026 |
| 36C24626N0410 | Exelan Pharmaceuticals Inc LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC. | $5.1M | Jan 14, 2027 |
| 36C24626N0416 | Exelan Pharmaceuticals Inc LENALIDOMIDE FOR THE DURHAM VAMC FOR PATIENT CARE | $4.5M | Jan 14, 2027 |
| 36C24626N0420 | Exelan Pharmaceuticals Inc LENALIDOMIDE FOR THE RICHMOND VAMC FOR PATIENT CARE | $4.1M | Jan 14, 2027 |
| 36C25726N0205 | Novartis Pharmaceuticals Corporation LU177 - PLUVICTO/LUTATHERA | $4.2M | Feb 6, 2027 |
| 36C25722P0417 | Boston Scientific Corp Y90 GLASS MICROSPHERES | $4.0M | Apr 22, 2027 |
| 36C24722N0171 | Progenics Pharmaceuticals Inc FLUORINE 18 PIFLUFOLASTAT - PYLARIFY | $5.7M | Apr 30, 2027 |
| 36C25924P0003 | Sofie Co. PET/CT RADIOPHARMACEUTICALS | $5.1M | Sep 30, 2027 |
| 36C26127N0063 | Novartis Pharmaceuticals Corporation PLUVICTO NDC: 69488-0010-61 | $4.1M | Sep 30, 2027 |
Common questions
Who are the top VA contractors for NAICS 325412?
In the latest 12 months, Mckesson Corporation ($10.8B), Exelan Pharmaceuticals Inc ($100.1M), Novartis Pharmaceuticals Corporation ($39.3M) received the most VA obligations for pharmaceutical preparation manufacturing.
How concentrated is this market?
The eight largest primes held 99.3% of positive obligations, and Mckesson Corporation alone held 97.2%. 19 contractors won their first obligations in this market during the latest 12 months.
Are any large VA NAICS 325412 contracts ending soon?
10 of the largest awards in this market reach their current end date in the next 18 months. The first is 36C26226N0112 (Novartis Pharmaceuticals Corporation, $4.3M obligated), ending Oct 31, 2026. An end date is a research lead, not a confirmed recompete: options and extensions often move it.
Related markets
NAICS 325412 across all agencies
HHS · NAICS 325412
$777.8MDOJ · NAICS 325412
$200.6MDoD · NAICS 325412
$64.7MFigures are net obligations on prime contracts (award types A–D) from USAspending.gov, grouped by funding agency and the NAICS code on each award. Net obligations include deobligations and corrections, so they can differ from positive-obligation totals. See methodology.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.